Lyell Immunopharma, Inc. SEC filings LYEL
Lyell Immunopharma, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 20, 2020. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 21, 2026 | — |
| CORRESP | Letter to the SEC | Jul 17, 2026 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2026 | — |
| EFFECT | Filing | Apr 14, 2026 | — |
| CORRESP | Letter to the SEC | Apr 13, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2026 | — |
| EFFECT | Filing | Dec 15, 2025 | — |
| CORRESP | Letter to the SEC | Dec 11, 2025 | — |
| EFFECT | Filing | Aug 15, 2025 | — |
| CORRESP | Letter to the SEC | Aug 13, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2025 | — |
| EFFECT | Filing | Jul 30, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2025 | — |
| EFFECT | Filing | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 3, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2024 | — |
| EFFECT | Filing | May 3, 2024 | — |
| CORRESP | Letter to the SEC | May 1, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2024 | — |
| EFFECT | Filing | Jun 16, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 16, 2021 | — |
| CERT | Filing | Jun 16, 2021 | — |
| 8-A12B | Filing | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| CORRESP | Letter to the SEC | Jun 1, 2021 | — |
| CORRESP | Letter to the SEC | May 28, 2021 | — |
| SEC STAFF LETTER | Filing | May 28, 2021 | — |
| UPLOAD | Letter from the SEC | May 25, 2021 | — |
| DRSLTR | Filing | May 12, 2021 | — |
| DRS/A | Filing | May 12, 2021 | — |
| UPLOAD | Letter from the SEC | May 7, 2021 | — |
| DRS | Filing | Apr 12, 2021 | — |
| D | Filing | Mar 20, 2020 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LYEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806952
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.